C&R Research Swings to Profit in Q2 on CRO Growth, Lands $160B in OrdersC&R Research posted KRW 17.7 billion on second-quarter revenue and swung back to profitability,signaling a strong recovery in its core business. With a robust order backlog of KRW 160 billion, expectations are rising for an even stronger financial performance in the second half of the year. For more details, please check the link below.   Read Full Article  | Source: Bizwatch

    Clinical Trial Outsourcing Demand Growing from China and Japan...Targeting More Big Pharma ContractsC&R Research plans to raise its new contract target to KRW 120 billion and push toward becoming a Global Top 20 CRO, driven by its multi-country clinical trial platform and expanded AI-powered clinical automation.For more details, please refer to the link below.Read the full article | Source: Seoul Economic Daily

    AI-Driven Data CRO Transformation and Northeast Asia Clinical NetworkGL Research expects C&R Research to deliver continued growth and improved profitabilitythrough its transition to an AI-driven data CRO model and the expansion of its global multi-regional clinical trial business.For more details, please refer to the link below.Read the Original Article | Ref: MoneyToday

    Asian Global CRO Strategy takes shape across China, Japan and Southeast AsiaC&R Research is strengthening its global CRO capabilitiesby expanding its Asia-wide clinical trial network spanning China, Japan and Southeast Asia.For more details, please refer to the link below.Read the Original Article | Ref: ConsumerTimes

    [Interview] Byungkwan Park, Head of CDSA DivisionC&R Research is accelerating its transformation into a data-driven CRO positioned to lead the global marketby building an AI- and data-powered clinical operations framework centered around its CDSA Division.By advancing AI-enabled workflow innovation and data-driven decision-making,the company is enhancing the efficiency and quality of clinical operations.For more details, please refer to the link below.Read the text | Ref: THE BIO

    Partnership with Japanese CRO Strengthens Regional Capabilities and Accelerates Expansion Across AsiaC&R Research has acquired an equity stake in EPS International Korea Ltd., the Korean subsidiary of Japan's EPS Group, marking a significant step toward establishing an integrated clinical development platform spanning Korea, China, and Japan.Through this acquisition, C&R Research strengthens its collaborative foundation with a leading Japanese CRO and further accelerates its expansion into the broader Asian clinical research market.For more details, please refer to the link below.Read the text | Ref: Hankyung